The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Background: Recently, immune checkpoint inhibitors (ICIs) have been proved one of the most promising anti-cancer therapy, series clinical trials have confirmed their efficacy. But they are also associated with distinctive set of toxic effects, which are recognized as immune-related adverse events. A...
Main Authors: | Ke Ma, Yali Lu, Shanshan Jiang, Jiangong Tang, Xin Li, Yuyang Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.01430/full |
Similar Items
-
Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis
by: Cui P, et al.
Published: (2017-09-01) -
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
by: Chuzi S, et al.
Published: (2017-06-01) -
The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials
by: Siyao Deng, et al.
Published: (2019-09-01) -
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
by: Kyoichi Kaira, et al.
Published: (2021-03-01) -
Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01)